Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman — Neutral
REPL GlobeNewsWire — August 15, 2025SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al.
OMAH: I'd Rather Just Own Berkshire Hathaway — Neutral
BRK-A BRK-B OMAH Seeking Alpha — August 15, 2025OMAH is an ETF built on Berkshire Hathaway's securities portfolio. It earns a high 15% distribution yield selling covered calls on the portfolio. Berkshire's investment approach and long-term value focus argue that its stock portfolio should rise long term. So, OMAH's covered call writing should hold back long term gains.
Applied Materials shares slide on weak Q4 guidance — Negative
AMAT Proactive Investors — August 15, 2025Applied Materials Inc (NASDAQ:AMAT, ETR:AP2) shares fell 13.2% on Friday after the semiconductor equipment maker issued weaker-than-expected guidance for the fourth quarter. The company expects revenue around $6.7 billion and EPS near $2.11, both below analysts' forecasts of $7.32 billion and $2.38.
Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman — Neutral
SRPT GlobeNewsWire — August 15, 2025SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta's medication intended for the treatment of Duchenne muscular dystrophy. This news prompted another significant decline in the price of Sarepta (NASDAQ: SRPT) shares.
Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over “Inflated Guidance” – Hagens Berman — Neutral
CNC GlobeNewsWire — August 15, 2025SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results.
NICE Grows Through Expanding Portfolio and Strong Partnerships — Positive
NICE Zacks Investment Research — August 15, 2025NICE rides cloud growth, AI-driven CXone adoption, and deepened Salesforce ties to boost revenue and expand customer reach.
Petrobras Q2 Earnings Miss on Oil Price Drop, Production Grows — Negative
PBR Zacks Investment Research — August 15, 2025PBR posts lower Q2 earnings on weaker oil prices despite higher production, while boosting dividends and investments.
Cardinal Health to Acquire Solaris Health for Urology Expansion — Positive
CAH Zacks Investment Research — August 15, 2025CAH is set to buy Solaris Health for $2.4B, boosting urology presence with 750+ providers and expanding Specialty Alliance reach.
Can Eylea HD and Dupixent Profits Revive Regeneron Stock? — Positive
REGN Zacks Investment Research — August 15, 2025REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea — Positive
NYXH Zacks Investment Research — August 15, 2025NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
Marex Group (MRX) Faces Investor Scrutiny Amid Short Seller Accusations – Hagens Berman — Neutral
MRX GlobeNewsWire — August 15, 2025SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- On August 5, 2025, investors in Marex Group plc (NASDAQ: MRX) saw the price of their shares significantly decline in the wake of a critical short report accusing the company of engaging in an improper multi-year accounting scheme.
Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy — Neutral
AMAT MarketBeat — August 15, 2025Applied Materials NASDAQ: AMAT gave its market a reason to sell with its Q3 results. However, the 15% pre-market decline is a knee-jerk reaction to news that opens up a solid buying opportunity.
Applied Materials sinks 13% on weak guidance due to China demand — Negative
AMAT CNBC — August 15, 2025Applied Materials topped Wall Street's third-quarter earnings estimates but issued light guidance due to macroeconomic pressures. CEO Gary Dickerson said the current macroeconomic backdrop and trade issues have fueled "increasing uncertainty and lower visibility," primarily within its China business
Will AI-Driven Fiber Boom Boost MasTec's Communications Business? — Positive
MTZ Zacks Investment Research — August 15, 2025MTZ posts record Q2 results as AI-fueled fiber demand propels 42% growth in its Communications segment and a $5B backlog.
Sandisk Stock Drops as Profit Estimates Come Up Short on Fab Startup Costs — Negative
SNDK Investopedia — August 15, 2025Sandisk (SNDK) shares slumped Friday, a day after the maker of computer flash drives gave lower-than-expected profit guidance as startup costs increase.
Ondas Holdings Inc. Announces Closing of $173 Million Public Offering Including Full Exercise of Overallotment Option — Neutral
ONDS Accesswire — August 15, 2025BOSTON, MASSACHUSETTS / ACCESS Newswire / August 15, 2025 / Ondas Holdings Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of private industrial wireless networks and commercial drone and automated data solutions through its Ondas Networks and Ondas Autonomous Systems business units, announced today the closing of its underwritten public offering of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriter of their over-allotment option. Ondas estimates net proceeds from the offering to be approximately $163 million, after deducting underwriting discounts and commissions and estimated …
ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript — Neutral
ICCC Seeking Alpha — August 15, 2025ImmuCell Corporation (NASDAQ:ICCC ) Q2 2025 Earnings Conference Call August 15, 2025 9:00 AM ET Company Participants Michael F. Brigham - President, CEO, Treasurer, Secretary & Director Timothy C.
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs — Positive
AZN Zacks Investment Research — August 15, 2025AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.
PPG Gains on Cost Actions and Acquisitions Amid Demand Softness — Negative
PPG Zacks Investment Research — August 15, 2025PPG rides cost cuts, acquisitions and price hikes to offset weak demand in Europe and industrial coatings softness.
HOOD's July 2025 DARTs Jump: Is Product Suite Expansion Paying Off? — Positive
HOOD Zacks Investment Research — August 15, 2025Robinhood's July DARTs surge across equities, options and crypto, as rapid product launches draw more active traders to its platform.
